Mina Thabet Kelleni

Learn More
Editorial In the past few years, rituximab has been recognized as a safe and effective emerging treatment for autoimmune hemolytic anemia (AIHA) [1,2]. Rituximab was also considered as a preferred second-line therapy of warm antibody hemolytic anemia in adults in some major European centers and it was shown that second-line treatment with rituximab led to(More)
Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study was to investigate the possible protective role of the antidiabetic drugs metformin (250 mg/kg dissolved in DW p.o. for seven days) and sitagliptin (10 mg/kg dissolved in DW p.o. for seven days) in a model of DOX-induced (single dose(More)
Hepatitis C virus (HCV) is the leading cause of chronic liver disease, including cirrhosis and cancer, and liver transplantation. Undoubtedly, effective antiviral therapy is highly essential for achieving sustained virological response (SVR) in HCV-infected patients [1,2]. Simeprevir (SMV) is a macrocyclic NS3/4A HCV protease inhibitor with a potent(More)
  • 1